How do bone-active drugs increase patient survival?

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1079522

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Bisphosphonates are a class of drugs used to prevent bone destruction in diseases such as osteoporosis. Evidence is emerging that these drugs also act on cells outside the skeleton to have additional beneficial effects, for example prolonging patient survival. This project will identify the cells affected and the mechanisms involved. With this knowledge, these drugs could be used more effectively and in different ways for the prevention or treatment of cancer and chronic human illnesses.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $613,952.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Pharmacology and Therapeutics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bone disease | breast cancer | macrophages | monocytes | tumour targeting

Related Links